EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GPX2+ tumor cells recruit LGALS1+ B cells via CCL26-CCR3 axis to promote immunosuppression and tumor progression in hepatocellular carcinoma

Liang Lin, Shiye Yang, Jixiang Zhang, Guodu Chen, Wuhan Zhou, Dongxing Chen, Jiafei Chen

Frontiers in Immunology · 20.03.2026 · 17

DOI: 10.3389/fimmu.2026.1709855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 20.03.2026. Verfasst von Liang Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The First Hospital of Putian City, Putian, Fujian, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Glutathione Peroxidase, B-Lymphocytes. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The molecular link between Hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC) progression remains elusive. Here, we identify glutathione peroxidase 2 (GPX2) as a pivotal mediator of this process. Single-cell analysis of HBV-positive HCC reveals a distinct GPX2 + CSC population characterized by high MYC and CD44 expression. We demonstrate that GPX2 preserves stemness intrinsically by mitigating ROS-mediated c-MYC nuclear-cytoplasmic distribution, while extrinsically fostering immune evasion via the CCL26-CCR3 signaling axis. specifically, GPX2-derived CCL26 recruits and educates B cells towards an immunosuppressive LGALS1 + state, which predicts adverse patient outcomes. In vivo , GPX2 overexpression accelerates tumorigenesis, whereas targeting CCR3 with ALK4290 sensitizes tumors to anti-PD-1 checkpoint blockade. These findings delineate a dual mechanism whereby GPX2 couples oxidative stress regulation to immune modulation, positioning the GPX2-B cell axis as a promising therapeutic target for HBV-driven liver cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularGlutathione PeroxidaseB-LymphocytesChemokines, CCHumansAnimalsDisease ProgressionSignal TransductionCell Line, TumorMiceNeoplastic Stem CellsHepatitis B virusReactive Oxygen SpeciesOxidative Stress

Stichwörter der Autor:innen

B cellCSCsGPX2HBV-positive HCCROS

Substanzen

Glutathione PeroxidaseGPX2 protein, humanChemokines, CCReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, The First Hospital of Putian City, Putian, Fujian, China.
  • Department of Comprehensive Surgery, Nantong First People's Hospital, Affiliated Hospital 2 of Nantong University, Nantong, Jiangsu, China.
  • General Surgery Department I, Zhongshan City People's Hospital, No. 2, Zhongshan, Guangdong, China.

Zitieren

APA

Lin, L., Yang, S., Zhang, J., Chen, G., Zhou, W., Chen, D., & Chen, J. (2026). GPX2+ tumor cells recruit LGALS1+ B cells via CCL26-CCR3 axis to promote immunosuppression and tumor progression in hepatocellular carcinoma. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1709855

Vancouver

Lin L, Yang S, Zhang J, Chen G, Zhou W, Chen D, et al. GPX2+ tumor cells recruit LGALS1+ B cells via CCL26-CCR3 axis to promote immunosuppression and tumor progression in hepatocellular carcinoma. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1709855

BibTeX
@article{Lin2026,
  author = {Lin, Liang and Yang, Shiye and Zhang, Jixiang and Chen, Guodu and Zhou, Wuhan and Chen, Dongxing and Chen, Jiafei},
  title = {GPX2+ tumor cells recruit LGALS1+ B cells via CCL26-CCR3 axis to promote immunosuppression and tumor progression in hepatocellular carcinoma},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1709855}
}
Kostenlos starten →